1 December 2025 in APL Bioengineering
Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer accounting for a majority of cases. Despite advances in targeted therapies and immunotherapy, challenges such as tumor heterogeneity, resistance mechanisms, and limited preclinical models hinder treatment efficacy. Traditional cancer models, including 2D cell cultures and animal models, often fail to accurately replicate the lung's complex architecture, microenvironment, and biomechanical cues, leading to poor predictive performance in drug development. Microfluidic-based organ-on-a-chip technology offers a promising alternative by integrating human-derived cells with precisely controlled perfusion, mechanical cues, and tumor–stroma interactions in physiologically relevant 3D models. These platforms enable the study of lung cancer biology, drug responses, and patient-specific therapeutic outcomes with improved accuracy. In this review, we discuss recent advancements in microfluidic systems for recapitulating normal lung physiology and 3D lung cancer microenvironment, covering various microfluidic platforms with applications in disease modeling and drug testing. Unlike other review articles, we bring first-hand insights from clinicians about the current treatment practice for lung cancer and the clinical utilities of lung cancer-on-a-chip models, which bioengineers have been seeking. We also highlight the translational potential of these systems in personalized oncology and the need for interdisciplinary collaborations, particularly with clinicians, to enhance their clinical impact.
1 November 2025 in Journal of Thoracic Disease
Background: Prolonged air leak (PAL) is a common complication after lung resection for non-small cell lung cancer (NSCLC). This retrospective cohort study investigates the association between computed tomography (CT)-based emphysema score and PAL in patients undergoing lung resection for NSCLC. Methods: Patients who underwent lung resection for pathological stage I–IIIA NSCLC at a single institution [2010–2021] were identified. Exclusion criteria included neoadjuvant therapy, missing preoperative chest CT, pneumonectomy, or bilobectomy. Chest CT-based emphysema score was defined as the percentage of emphysematous lung [density <−950 Hounsfield units (HU)] in the ipsilateral lung. PALs were defined as those lasting more than 5 days. Univariable and multivariable logistic regression analyses were conducted. Results: Among 550 patients, 58% (321/550) were female and 77% (425/550) were White. Approximately 67% (366/550) underwent a lobectomy, of which 67% (246/366) were upper lobe resections. Additionally, 79% (432/550) of patients underwent minimally-invasive surgery and 9% (48/550) developed a PAL. On multivariable analysis, after adjusting for age, gender, body mass index (BMI), surgical approach, lobe operated upon, procedure performed, pack-years and tumor size, percentage of emphysema [odds ratio (OR) =1.04; 95% confidence interval (CI): 1.01–1.07; P=0.02], lobectomy (OR =2.59; 95% CI: 1.04–6.41; P=0.040) and history of cardiothoracic surgery (OR =3.50; 95% CI: 1.53–8.03; P=0.003) were associated with PAL. We identified 16% as the optimal emphysema score cut-point for predicting PAL, with sensitivity of 38%, specificity of 76%, and accuracy of 73%. Conclusions: CT-based emphysema score is associated with PAL following lung cancer resection and may help guide intraoperative planning and patient counseling.